Merck Q2 Earnings and Revenue Miss Estimates
- ByTipRanks-
Merck (MRK) delivered second-quarter financial results that fell short of Wall Street expectations, despite reflecting year-over-year growth. Worldwide sales from continuing...
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Merck & Company Inc (MRK)
76.41
+0.23(+0.30%)
- Volume:7,821,226
- Bid/Ask:76.40/76.41
- Day's Range:76.19 - 76.81
MRK Overview
- Prev. Close
- 76.18
- Day's Range
- 76.19-76.81
- Revenue
- 47.1B
- Open
- 76.36
- 52 wk Range
- 68.38-83.72
- EPS
- 1.89
- Volume
- 7,821,226
- Market Cap
- 192.89B
- Dividend (Yield)
- 2.60(3.38%)
- Average Volume (3m)
- 11,430,936
- P/E Ratio
- 40.32
- Beta
- 0.43
- 1-Year Change
- -0.43%
- Shares Outstanding
- 2,532,058,364
- Next Earnings Date
- 27 Oct 2021
What is your sentiment on Merck & Company Inc?
or
Vote to see community's results!
Merck & Company Inc News
- U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.44%
- ByInvesting.com-
Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Consumer Goods, Basic Materials and Oil & Gas sectors propelled shares higher. At the close in...
- Merck Sees Recovery in Non-COVID Vaccine Demand as Quarterly Sales Beat Estimates
- ByFXEmpire-
(Reuters) -Merck & Co reported quarterly revenue on Thursday that topped Wall Street estimates, as sales of its Gardasil vaccine bounced back and demand for blockbuster cancer drug...
Merck & Company Inc Analysis
- Merck & Co., Inc. 2021 Q2 - Results - Earnings Call Presentation
- BySeeking Alpha-
- An Improving Outlook For Merck
- BySeeking Alpha-
- Merck & Co.: A Wide Moat Business At A Discounted Price
- BySeeking Alpha-
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Neutral | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Buy |
| Summary | Strong Buy | Buy | Strong Sell | Sell | Strong Buy |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 104.00 | 104.00 | 102.50 | +1.50 | +1.46% | 16.74K | London | |||
| 365.00 | 365.00 | 358.00 | +4.00 | +1.11% | 181.71K | London | |||
| 215.50 | 215.50 | 215.50 | 0.00 | 0.00% | 0.00 | London | |||
| 52.50 | 52.50 | 52.50 | -1.00 | -1.87% | 15.00K | London | |||
| 698.00 | 710.00 | 688.11 | +3.00 | +0.43% | 16.55K | London | |||
| 233.20 | 235.90 | 230.30 | +1.50 | +0.65% | 5.05M | London | |||
| 13.01 | 13.50 | 12.76 | +0.01 | +0.08% | 499.32K | London | |||
| 174.85 | 177.95 | 174.35 | +0.15 | +0.09% | 12.40M | London | |||
| 17.20 | 18.35 | 17.20 | -1.25 | -6.78% | 658.80K | London | |||
| 94.00 | 97.20 | 93.85 | +0.50 | +0.54% | 500.77K | London | |||
| 46.24 | 46.65 | 45.00 | -0.26 | -0.56% | 124.95K | London | |||
| 103.14 | 104.12 | 101.90 | -0.34 | -0.33% | 28.81M | London | |||
| 441.00 | 452.20 | 435.60 | +4.30 | +0.98% | 5.18M | London | |||
| 117.70 | 117.78 | 116.50 | +0.90 | +0.77% | 43.29M | London | |||
| 46.85 | 47.32 | 46.28 | +0.62 | +1.33% | 112.34M | London |
Merck & Company Inc Company Profile
Merck & Company Inc Company Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Read More
- 2021-02-22 16:15:20What happen to MRK ? Time to buy ?
- 2020-10-15 17:58:18it will cross 81 in coming days
- 2019-03-04 02:57:45
The immuno-oncology drugs are promising, but $81.65 seems a bit over-excited. It's no cure, just prolonging life a small amount in end-stage patients who were resistant to normal treatments. A pullback to $70 on the cards in the next 6months would be realistic.- 2021-02-05 17:34:41
nice input - 2021-02-05 17:35:29nice input
- 2019-01-31 22:14:48
It will be going up - 2017-12-26 08:26:37Position buy will be up price
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.